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ABSTRACT 
 
Background: The Medical Technologies Evaluation Programme (MTEP) of NICE in England aims to 
evaluate medical devices that are deemed to be cost-saving or cost-neutral and produce medical 
technology guidance (MTG) to encourage their adoption. 
Objective: To review the MTGs since MTEP’s inception in 2009 until February 2017. 
Methods: One researcher assessed all published MTGs and extracted data on the clinical and economic 
evidence supporting each technology. The NICE Committee’s decision outcome for each assessment was 
also recorded. A qualitative analysis was performed on technologies that were not supported for adoption 
to identify the main drivers of the decision.  
Results: 31 MTGs were reviewed. The committee fully supported the medical devices in 14 MTGs, 11 
were partially supported and 6 not-supported. 58% of the MTGs had no RCT data available and the main 
source of evidence came from non-experimental studies. There was no statistically significant difference 
in the average number of RCTs and non-experimental studies between the fully supported, partially 
supported and not supported technologies. Whilst all the fully supported MTGs demonstrated cost-saving 
results only 50% of the not-supported MTGs did. The sponsor estimated a higher average cost-saving 
than the EAC in most of cases (20/31). The qualitative evaluation suggests that the main drivers for 
negative decisions were the quantity or quality of studies, and cost incurring results in the economic 
evaluation.  
Conclusions: The main drivers of the decision-making process are the quality and quantity of the 
submitted evidence supporting the technologies, as well as the economic evaluation results.   
 
Key Words: Medical Technologies, Technology Assessment, NICE, Health Technology Assessment, 
NHS.  
 
Key points for decision makers: 
• From its inception in 2009 until February 2017, NICE developed 31 Medical Technologies 
Guidance (MTG), fully supporting the adoption of 14 technologies and partially supporting 11.  
• The decision to recommend a technology relied on the quantity and quality of the available 
clinical evidence, as well as the results of the economic evaluation analysis.  
• Most supported MTGs were not supported by randomized controlled trials, and instead reied on 
other sources of evidence such as non-randomized studies, case reports, and expert opinion.  
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1.1 ACRONYMS 
 
 
CG Clinical Guidelines (Programme) 
DAP Diagnostics Assessment Programme 
EAC External Assessment Centre 
HST Highly Specialised Technologies 
HTA Health technology assessment 
IP Interventional Procedures 
MTAC Medical Technologies Advisory Committee 
MTEP Medical Technologies Evaluation Programme 
MTG Medical Technology Guideline 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
RCT Randomised Controlled Trial 
TAP Technology Appraisal Programme 
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1.2 INTRODUCTION 
 
1.2.1 Background 
Health technology assessment (HTA) has been increasingly adopted worldwide as a mechanism 
for efficient resource allocation in health care. HTA is defined as “the systematic evaluation of the 
properties and effects of a health technology, addressing the direct and intended effects of 
this technology, as well as its indirect and unintended consequences, and aimed mainly at informing 
decision making regarding health technologies.” [1,2]. The National Health Service (NHS) in the United 
Kingdom, an early adopter of HTA, holds leadership position in this field. The HTA programme in the 
UK was launched in 1993, aiming to foster the use of systematic reviews to guide the adoption of health 
technologies in the NHS [3].  The HTA programme preceded the National Institute for Health and Care 
Excellence (NICE, originally named National Institute of Clinical Excellence), which was set up as an 
independent public body in 1999 [3]. NICE's role is to improve outcomes for people using the NHS and 
other public health and social care services, by producing evidence-based guidance and advice for health 
and social care practitioners and the public.  
NICE is currently responsible for the evaluation of new health technologies. The Medical 
Technologies Evaluation Programme (MTEP) identifies and selects medical technologies that would 
benefit from national evaluation. Set up in 2009 [4], the MTEP aims to critically appraise the evidence 
supporting medical devices and diagnostics and produce guidance to encourage their adoption, promoting 
a rapid incorporation of beneficial medical technologies in the NHS and “collaborative research” between 
sponsors and the NHS [5]. The MTEP routes the selected technologies to 6 different technology 
evaluation programmes. [5]: Technology Appraisals (TAP), Highly Specialised Technologies (HST), 
Diagnostics Assessment (DAP), Medical Technologies Guidance (MTG), Clinical Guidelines (CG) and 
Interventional Procedures (IP). The TAP evaluates technologies such as drugs, devices, systems of care 
and others, prioritising these technologies based on criteria such as the target population, disease severity, 
and economic impact [6]. The HST evaluates treatments for ultra-orphan conditions. The DAP is focused 
on the evaluation of diagnostic technologies that could improve health outcomes but are likely to imply 
higher costs for the NHS [7]. The CG programme provides evidence-based recommendations for services 
and activities in diverse settings, from the clinical management of conditions, medicines, social care, to 
interventions oriented to improve health at the community-level [8]. The IP programme evaluates 
interventional procedures in terms of efficacy and safety [9]. Technologies are selected for MTG if they 
are likely to be cost saving or cost neutral, and can be evaluated as a single technology and in a short time 
scale [5].  This study focuses on the MTGs produced by the MTEP. 
Medical devices differ from other medical interventions, such as pharmaceuticals [10,4,11]. In 
terms of effectiveness, medical devices may change their effectiveness through time due to modifications, 
they are user-dependent and have a “learning curve”, which depends on the technology uptake [12]. Also, 
the effectiveness of the diagnostics depend on subsequent treatment and the medical devices may be used 
for different medical conditions in different settings – with different effectiveness. Regarding clinical 
evidence, it is usually limited, generally lacking randomised studies. This may be because the product life 
spans of devices are generally shorter than for pharmaceuticals, which may imply a negative incentive for 
evidence production [11]. The benefits at a health system level depend on “organizational factors” 
(setting, staff) and costs may involve running as well as procurement costs. Finally, medical devices 
prices are usually more dynamic than other interventions [13].The MTG was established in recognition of 
these special characteristics of the medical devices, which made them less suitable for the established 
pathways [4].  
1.2.2 Medical Technologies Guidance 
For medical technologies routed to the MTEP for MTG , the MTEP produces an adoption 
recommendation in a Medical Technology Guidance (MTG) [5]. However, unlike TAP 
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recommendations, a positive adoption recommendation from MTEP does not carry a funding mandate for 
NHS England.  
 
The current process of the MTEP programme is described in Figure 1. The MTAC, composed of 
around 25 voluntary members including clinicians with expertise with the respective medical 
technologies, scientists, healthcare regulations experts, and representatives with experience in the medical 
technologies industry, identifies and selects medical technologies [5]. The sponsors (usually product 
developers) present their medical technology for evaluation to NICE and then completes a submission 
based on the defined scope, providing clinical evidence and an economic evaluation model [5]. The 
External Assessment Centres (EACs), which are typically academic bodies commissioned by NICE, 
check or assess the clinical evidence and economic evaluation presented by the sponsor [5]. Also, expert 
advisers who offer additional information and clinical opinions to the committee [10]. The public  may 
attend the committee meetings and comment at the consultation on the draft guidance.[5]. Finally, the 
MTAC evaluates all these inputs and generates the MTG.  
 
The MTEP has a Research Commissioning workstream, which is part of NICE’s Research 
Recommendations process [14]. The Research Commissioning workstream facilitates research to address 
the gaps identified by the Medical Technologies Advisory Committee (MTAC) in the guidance 
recommendations [15]. Evidence generated is expected to inform future reviews of the MTGs. 
 
1.2.3 Previous research 
Several previous studies have reviewed NICE’s MTEP programme. Cowles et al in 2017 
compared different NICE HTA programmes, appraising their impact on the allocative efficiency in the 
NHS. This study showed that MTEP differs from other NICE guidance-producing programmes in 
important ways. First, the manufacturer prepares the evidence report (with a review by the EAC), which 
differs from the DAP, CG and TAP streams where the evidence is presented by the EAC or the evidence 
review group (ERG). Second, unlike other programmes, the MTEP does not have an appeal process. 
Third, MTEP does not use a reference case (unlike IP, TAP and HST programmes) [16]. Green et al in 
2014 also compared the MTEP with other HTA programmes. By comparing the methods guides, the 
authors reported that in the TAP, RCTs are stated as the most valid source of evidence, and in the MTEP 
no preferred source is defined. Also, unlike the TAP process, expert advisors are considered in the MTEP 
as part of the evidence synthesis process, which Green et al 2014 found to be potentially unreliable [17]. 
Chapman et al in 2014 did an initial assessment of the programme, through an evaluation of the MTEP 
aims and initial outcomes. The authors concluded that some barriers persist. For instance, the small 
manufacturers are underrepresented in the programme submissions. Also, they found that the programme 
has not effectively reduced the evaluation timeline compared to other programmes [4]. Finally, Alshreef 
et al in 2016 reviewed the economic evaluations of 12 MTGs, identifying the criticisms raised by the 
EAC to the sponsor’s submission and the committee’s considerations. They found that the sponsor’s 
identification and measurement of costs and consequences accounted for 42% of the EAC’s criticisms 
[11].  
1.2.4 Objectives 
To the best of our knowledge, no study so far has reviewed the full sample of published MTG  to 
date (2017), aiming to evaluate the evidence supporting MTAC assessments, and the main drivers behind 
the decision on adoption of the technologies. This study addresses this gap in the literature.  
This work is based on a review of published MTGs. It summarizes the final recommendations 
and cases for adoption of the evaluated guidance reports and characterises the clinical evidence and 
economic evaluation presented in the guidance reports. 
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1.3 METHODS 
 
All NICE MTGs published between 2009 to February 2017, from the NICE electronic database, 
were included. When information was missing in the guidance reports, data from the associated EAC 
Report and the sponsor’s submission were extracted.  
1.3.1 Data extraction  
A standardised electronic data extraction form was created in Microsoft Excel. Information about 
each guidance was extracted. Each guidance was assessed by a single reviewer and afterwards discussed 
among all the investigators.  
1.3.2 Parameters evaluated 
The guidance reports were reviewed to extract both general information about the clinical area 
and technology and detailed information on the clinical and economic evidence supporting it (Supplement 
1).  
First, the clinical area of each MTG was evaluated and categorised. For the clinical care setting, 
the following categories were considered: Hospital, Secondary Care, Primary Health Care and 
Community Level. Regarding the committee’s suggestion on routine adoption, 3 categories were adopted 
by merging the 5 categories of recommendations defined in the methods guide [4]: Fully Supported (FS) 
(which refers to: Case for adoption is fully supported), Partially Supported (PS) (which refers to: Case for 
adoption is partially supported; or Case for adoption is partially supported and technology has potential to 
provide significant patient or healthcare system benefits) and Not Supported (NS) (which refers to: Case 
for adoption is not currently supported but technology has potential to provide significant patient or 
healthcare system benefits; or Case for adoption is not supported and technology does not have potential 
to provide significant patient or healthcare system benefits). When the medical technology was 
categorised as “Partial Support”, a description of partial support was noted.  
Also, information about the Research Commissioning workstream was extracted. Some of the 
partially-supported and not-supported MTGs are selected for Research Recommendations [10]. The 
decision to select MTGs for further research typically depends on the nature of the evidence gap, 
information about ongoing research, ethical or practical aspects of conducting additional research, and the 
likely costs and benefits of undertaking studies. The percentage of MTGs selected for research 
recommendations (section 1 of the MTG) and the number of studies that were completed was 
documented. Further, any subsequent reviews of the MTGs (if available) was described.  
Second, the clinical evidence submitted by the sponsor, studies added or rejected by the EAC, 
and the final evidence base available on the technology were evaluated. The evidence was categorised as 
RCT, non-experimental (such as case-control, cohort and cross-sectional studies) and 
unpublished/abstract studies. To capture all the relevant evidence, the unpublished/abstract RCTs were 
included in the RCT count. Only patient-based studies were included (and in vivo studies were excluded). 
Ongoing studies were not incorporated.    
Third, a reduced form of the CHEERS checklist was used to extract information on economic 
parameters [18]. Both from the sponsor’s submission or the EAC report, best and worst cost-saving (or 
cost-incurring) values per patient in Great British Pounds (GBP) were included. These values were 
extracted from the guidance, and were standardised to represent the best and the worst-case scenarios. In 
some reports, these worst and best-case values could arise from comparing the technologies to different 
comparators or in different sub-populations. For example, in MTG17, the minimum value is the cost 
saving when comparing the technology, Debrisoft, to a comparator Hydrogel while the maximum value is 
the cost saving when comparing it to other comparator, Larvae. The time horizon used in the economic 
evaluations for MTGs was also extracted. When the models developed by the sponsor and EAC used 
different time horizons (as was the case in MTGs 3, 6, 10, 28), a common time horizon used in both the 
sponsor and the EAC economic models was extracted. The changes made by the EAC in the sponsor’s 
7 
 
submission were assessed, focusing on the following areas: Clinical Pathway, Model clinical inputs, 
Costs, and Sensitivity Analyses. When the EAC made no changes to the submitted models, the sponsor’s 
values for cost-savings were extracted. Also, the NHS economic impact of adopting the technology, the 
value of the presented annual cost saving in GBP for the NHS resulting from adopting the technology was 
extracted.  
1.3.3 Qualitative Evaluation  
An in-depth qualitative evaluation of the not-supported guidelines was performed. The main 
criticisms made by the EAC on the sponsor’s presented clinical and economic evidence were summarised. 
This was followed by an independent appraisal of each not-supported MTG, based on the qualitative and 
quantitative information together. The aim of this secondary evaluation was to identify what were the 
main drivers underlying the negative outcome of the decision process.  
1.3.4 Statistical Analysis 
A Kruskall-Wallis test was performed to analyse if there were statistically significant differences 
in the average number in each type of clinical evidence and the number of participants per RCT between 
the 3 categories of MTG recommendations.  
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1.4 RESULTS 
 
1.4.1 MTG characteristics  
31 MTGs and their associated reports were assessed, published between March 2011 and 
February 2017. A summary of the general characteristics of the MTGs is presented in Table 1. Regarding 
the committee’s recommendation on adoption, 14 technologies were fully supported (45%), 11 were 
partially supported (36%) and 6 were not supported (19%) (Figure 2). On only 1 MTG (MTG11), the 
committee’s suggestion was unclear, and thus, was categorised as having partial support. The majority of 
the reasons behind the partial support were restrictions for a certain patient sub-population. The majority 
of technologies were targeted for tertiary care, i.e. hospital setting (77%). 
6 MTGs (19%) contained research recommendations (MTG 1, 5, 20, 21, 22 and 31). 5 (16%) led 
to development of research protocols by External Assessment Centres (MTG5, 20, 21, 22 and 31). 
Recommended research on MTG5 was completed and led to a publication [19], which was considered by 
NICE in 2016. NICE decided not to update MTG5 based on this new information. At the end of our study 
period, recommended research studies for MTG20, 21, and 22 were underway.  Recommended research 
for MTG31 was in design stage. 
1.4.2 Clinical evidence appraisal   
A summary of the clinical evidence for each guidance is presented in Table 2. The evidence 
submitted by the sponsor consisted of RCTs, non-experimental studies such as case-control studies, cross 
sectional studies, technical reports and technology registries. Abstracts and unpublished studies submitted 
by the sponsor were also reviewed. After its evaluation, the EAC added an average of 2 studies per MTG 
(Range: 0 – 14) and rejected an average of 9 studies per MTG for further evaluation (Range: 0 - 190). 
Overall, the EAC added 59 and rejected 278 studies. Several reasons were provided for rejecting studies: 
population was outside of the scope (MTG29 and 30), studies had overlapping cohorts (MTG27); there 
was double reporting of studies (MTG14, 17 and 16); studies did not assess the device being evaluated 
(MTG3); studies did not report outcomes or interventions defined in the scope (MTG12 and 22); small 
studies with limited follow-up (MTG16 and 26); and that studies did not address the decision problem 
(MTG21 and 13).  
Regarding the quality of the evidence, the majority of the MTGs did not present any RCTs for 
the committee’s evaluation (58%). The proportion of MTGs with one or more RCTs was non-
significantly lower for the fully-supported MTGs compared to those that were either not supported or 
partially supported (Figure 3). Also, the number of participants per RCT was not higher among fully-
supported technologies. On average, 29% of the fully-supported MTGs had 1 or more RCTs, less than the 
partially-supported (55%) and the not-supported (50%) MTGs. The fully-supported, partially-supported 
and not-supported MTGs did not have statistically significant differences regarding the number of RCTs 
(p= 0.7164), number of participants per RCT (p= 0.227), non-experimental (p= 0.192) or unpublished or 
abstract studies per guideline (p= 0.536). The fully supported MTGs had more than twice as many non-
experimental studies as the not-supported MTGs (Figure 4).  
1.4.3 Economic evaluation appraisal  
The economic evaluations submitted by the sponsors utilised different modeling approaches 
(Table 3, extended version in Supplement 2), most common being the decision tree, 20 (63%) followed by 
the Markov model, 5 (16%). The information regarding the model type was not available in 6 MTGs. 
Minimum and maximum cost-saving (or cost-incurring) values per patient calculated by the sponsor and 
the EAC are presented in the Supplement 3. The changes made by the EAC to the economic evaluation 
presented by the sponsor were assessed in 4 areas: clinical pathway, clinical and demographical inputs, 
costs and sensitivity analysis. In 15 MTGs the EAC suggested changes to the clinical pathway, in 22 
MTGs changes were proposed to the model clinical inputs, in 23 MTGs changes were proposed to the 
costs in the model and in 20 to the sensitivity analyses conducted in the economic evaluation. The 
minimum and maximum cost-saving estimated by the sponsor and the EAC were extracted from the 
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MTGs. A summary of the difference between the average values estimated by the sponsor and the EAC is 
presented in Figure 5. Despite the large variation among MTGs, the sponsor estimated a 57.9% higher 
average cost saving than the EAC, with a higher value in 20 cases (65%).    
Regarding the 6 not-supported MTGs, 2 were estimated to be cost-incurring on average (MTG 6 and 22). 
In one case (MTG 21) the EAC deemed it impossible to conduct an economic evaluation due to a lack of 
evidence to populate the economic model. In the 3 remaining cases (MTGs 5, 20 and 31), the EAC 
economic evaluation showed cost savings, which on average were between £8.5 and £2,244 per patient. 
In contrast, almost all of the fully-supported MTGs had estimated cost savings in their economic 
evaluations. The only exception was MTG 15, which had a slightly cost-incurring average value (-£7.1) 
per patient. Nevertheless, the experts included in the MTG 15 evaluation agreed that the cost-incurring 
scenario was unlikely, and that in the most probable clinical scenarios the technology was cost-saving.  
Only 5 MTGs included an analysis of the NHS overall cost saving incurred by adopting the 
technology (MTG 25, 28, 29, 30, and 32) into the healthcare system.  Of those, 2 had full support and 3 
partial support. The calculated potential annual cost-saving to the NHS ranged between £1,480,000 and 
£129,000,000. 
1.4.4 Key drivers of negative decisions  
a. Committee criticisms of the clinical evidence presented in the not-supported MTGs  
The committee’s evaluation of the clinical evidence was qualitatively assessed (Supplement 4). 
Overall, low quality or quantity of the clinical evidence was a dominant issue, specifically raised in all of 
the not-supported MTGs. Some of the specific reasons raised were small numbers of patients, lack of 
appropriate comparators, lack of evidence on long-term clinical outcomes, and lack of effect on the 
selected outcomes, low methodological quality and high risk of bias. For instance, in MTG20, the 
committee raised concerns about uncontrolled confounding in one of the studies. Another oft-cited issue 
raised by the committee in 4 of the not-supported MTGs was the lack of comparative evidence. Less 
frequently, the committee commented on the applicability of the presented evidence from outside of the 
United Kingdom (e.g., MTG 1 and 21).  
3 of the not-supported MTGs had RCTs. Despite the availability of RCTs in MTG 31 and 21, the 
RCTs did not evaluate the outcomes deemed as important by the committee. In MTG 5, the committee 
judged that the evidence did not consider a sufficient number of patients, ultimately lacking the power to 
demonstrate a statistically significant difference between the intervention and control groups.  
b. Committee criticisms of the economic evaluation presented in the not-supported MTGs 
Generally, most MTGs referred to the uncertainties in the presented cost models and the need for 
further research (Supplement 5). The majority of the not-supported MTGs were subject to committee 
criticism regarding model clinical inputs. In MTG 5, the committee reported problems with the cost 
calculations, as well as the level of uncertainty associated with model inputs. In MTG 21, due to the lack 
of clinical evidence, some relevant scenarios were deemed as not feasible to assess.  In the remaining 3 
MTGs (6, 20 and 22), the models did not consider all the relevant costs and resources involved (i.e., in 
MTG 20 the model included limited information on treatment costs and resource implications of having 
the disease; in MTG 22 the model did not capture potential savings from differences in diagnostic 
accuracy between current practice and the medical technology), which affected the results. Erroneous 
assumptions were criticized in some MTGs. For instance, in MTG 5 the clinical evidence was judged not 
to support the assumptions in the economic model, and in MTG 21 there was uncertainty about the 
validity of the assumptions. Also, the clinical pathway was criticized in some models. For example, in 
MTG 5 some important comparative alternatives were omitted. In other MTGs, the treatment pathway 
used in the model omitted stages that were considered relevant by the clinical experts and therefore, the 
model was not generalizable to the UK clinical practice. Other criticisms focused on the lack of clarity of 
the models submitted by the sponsor (MTG 6). In some cases, such as MTG 6, there was wide variability 
in results due to parameter uncertainty (i.e. the difference between current practice and the medical device 
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ranged from a cost saving of £195 to a cost increase of £536) and hence, it was not possible to draw 
certain conclusions about estimated cost savings associated with the technology.  
c. Main driver of decision-making  
Following an assessment of the most common criticisms of the not-supported MTGs, each MTG 
was evaluated individually by considering both the qualitative and quantitative evidence.  
In the case of Parafricta Boots (MTG 20), despite an EAC-estimated cost-saving ranging from 
£595 to £2799 per at-risk person, the committee decided that there was insufficient evidence to support 
the claimed clinical effectiveness of the technology. The available evidence included 2 case series, 2 
unpublished studies and 1 non-randomised trial. Regarding the latter, it was not clear if the results were 
biased by unassessed confounding factors.  
Mist (MTG 5) was also considered to be cost-saving according to its economic evaluation 
results. However, the quality of the published studies was deemed as insufficient to support the adoption 
of the technology, as the committee remained uncertain about clinical effectiveness. Although the 
available evidence included 2 RCTs and 8 non-experimental studies, the negative decision was due to the 
low number of participants and no comparators being included in the studies. Also, for chronic wounds 
there were no studies showing long-term outcomes.  
In the case of Ambulight PDT (MTG 6), the negative decision was primarily based on the lack of 
sufficient clinical evidence as well as the economic evaluation model that did not provide certain cost-
saving results. No RCTs were presented in support of the technology, and the evidence was based only on 
3 sources, 2 of which were unpublished data.  
In Humigard (MTG 31), even though the clinical evidence included 6 RCTs with 541 patients in 
total, evidence did not conclusively demonstrate an effect on reducing adverse outcomes (incidence of 
surgical site infections, length of stay in post-operative recovery and total hospital stay). A review of the 
RCTs suggested that most reported effectiveness in terms of pain reduction, with only 2 addressing other 
outcomes (core and wound temperature).  
In the case of Re-cell (MTG 21), although the available clinical evidence included 3 RCTs and 
13 unpublished sources, there was only limited information on the primary outcomes of interest, which 
subsequently impeded the development of a cost model by the EAC.  
Finally, no RCTs were presented for Vibratip (MTG 22) and the committee found the studies to 
be of low methodological quality. Therefore, there was a high level of uncertainty surrounding the 
diagnostic accuracy of the technology.  
 
 
1.5 DISCUSSION 
1.5.1 Summary of main findings  
The  review of the MTGs showed that the decision outcome in almost half of the 31 published 
MTGs to date fully supported the technology while the remaining MTGs recommended partial or no 
support. The majority of the fully-supported technologies were recommended in a tertiary care setting. 
Out of the 31 MTGs, about one fifth led to research recommendations.  
1.5.2 Clinical Evidence  
Interestingly, a lower proportion of fully-supported MTGs had 1 or more RCTs, as compared to 
that in partially-supported and not-supported MTGs. According to our statistical analysis, there was no 
difference in the number of randomized and non-randomized studies between the fully-supported, 
partially-supported and not-supported medical technologies. Nevertheless, this could be influenced by the 
low number of units. Although the design of a study provides only partial information about its rigor and 
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relevance to a given decision problem, randomized controlled trials are widely accepted as the gold 
standard for assessing the effectiveness of health care interventions.   
The majority of the completed MTGs (58%), irrespective of their outcome, did not include RCTs 
for the committee’s evaluation. However, this is not entirely surprising: unlike other programmes, the 
methods guide for MTEP does not state that RCT is the preferred source of evidence. This flexibility of 
not having RCTs as the preferred option may be warranted considering the fact that the majority of 
medical devices are developed by small and medium enterprises, as well as the complexity of conducting 
robust RCTs for medical devices. Drummond et al. (2009) previously pointed out the “additional 
challenges” associated with the generation of evidence on medical technologies. These are related to 
ongoing product modifications, which may have an impact on efficacy, the associated “learning curve” 
regarding the uptake of new devices, and the common unfeasibility of blinding, which may increase the 
risk of bias. Previous research also suggested that the efficacy of a medical device depends not only on 
the device but on the users characteristics, which might act as key confounders [20]. A concerted effort 
involving academic, industry, and regulatory experts is needed to evaluate the feasibility of designing and 
conducting RCTs of medical technologies. For example, Schnell-Inderst et al. have recently 
recommended wider use of adaptive trial designs to overcome the complexities of generating rigorous 
evidence on medical technologies [21]. In the absence of RCTs, the quality of the evidence supporting the 
use of many medical devices may be associated with increased uncertainty. Also, given the low number 
of MTGs that had RCTs, statistical methods to systematically combine treatment effects from randomised 
and not randomised studies, such as Bayesian methods, could be considered, utilising bias-adjusted 
evidence synthesis [22,21]. 
Overall, there was a high degree of consistency in the type and detail of information reported in 
the MTGs. However, in some MTGs (e.g., MTGs 2 and 6) it was unclear which study was submitted by 
the sponsor and which was added or rejected by the EAC. Furthermore, although MTGs provide a 
summary of the supporting studies, in some cases it was not possible to identify the type of the study, and 
determine whether it was a poster abstract or a peer-reviewed paper. In the future, MTGs should aim to 
have more homogeneity in their reporting, in order to increase comparability and facilitate the public 
evaluation of the process. However, it is also appreciated that MTG production is an evolving process in 
the changing landscape of the NHS and NICE.  
During our study period, almost one fifth of completed MTGs had research recommendations. 
While no MTGs were updated with new evidence generated from the Research Commissioning 
workstream, this was because the majority of studies were underway. The extent to which completed 
studies inform future reviews of MTGs should be evaluated in the long term.    
1.5.3 Economic Evaluation  
The assessment of supported and not-supported medical devices revealed differences regarding 
results of the economic evaluation. The majority of MTGs with full support had results that suggested the 
technology was cost-saving, but only 3 out of the 6 not-supported MTGs reported cost-saving results per 
patient. The analysis also revealed the impact of the EAC assessment on the evaluation and the results of 
economic evaluation. The EAC often made suggestions or changes in several components of the 
economic model, which materially changed the results in 26 of the reviewed MTGs. Of these 26, in 20 of 
the MTGs the sponsor estimated a higher cost-saving value than what was proposed by the EAC. This is 
expected, as the manufacturer’s evaluation tend to be higher than external review groups. In the majority 
of these 20 MTGs, the EAC made changes regarding the inputs, either clinical (16) or costs (17). For 
example, in MTG 2 the EAC stated that the hourly cost used by the sponsor was too high, in MTG 3 the 
sponsor used inaccurate cost data, in MTG 11 the sponsor did not include the VAT and in MTG 19 the 
EAC found an error in the hourly nursing costs. In 14 of those MTGs the EAC did further sensitivity 
analysis, and in 10 MTGs suggested changes to the clinical pathway.  
The reported cost-saving values in guidance documents were not always comparable between 
MTGs as they were expressed in different metrics. For example, in MTGs 7 and 14, the cost-saving was 
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calculated “per operation theatre”, while most of the other MTGs calculated the cost-saving per patient. 
The feasibility of adopting a common metric across all MTGs should be explored, as this would facilitate 
more meaningful comparisons on the cost impact of these technologies on the NHS.  
The MTEP methods guide states the following as one of the objectives of the programme: “to 
evaluate the impact of the technology on the healthcare system, alongside its clinical benefits for 
individual patients” [10]. Accordingly, all MTGs had a section regarding the NHS considerations, 
focusing on the healthcare system impact. However, information on NHS economic adoption impact was 
absent in 26 MTGs. Although the methods guide does not explicitly state the adoption impact to be a 
requirement for the MTGs, this parameter would be valuable for policymakers in the future when 
evaluating the economic implications of these technologies. The 5 MTGs that did incorporate this 
information were MTG 25, 28, 29, 30 and 32.  
1.5.4 What is the main driver of decision-making? 
Among the not-supported medical technologies, the decision was driven primarily by the quantity 
or quality of the presented evidence. Although some of the not-supported technologies had RCTs, either 
their outcomes were not clinically meaningful or had an insufficient number of patients. Some of the non-
experimental supporting studies had potential sources of bias or were unpublished. In 3 of the not-
supported MTGs the technologies were not deemed as cost-saving, or the economic evaluation could not 
be performed due to the lack of clinical evidence. 3 of the not-supported medical technologies were cost-
saving, in which case the lack of certainty about their effectiveness was the main driver for the negative 
recommendation. 
1.5.5 Further comments  
Although there is an initiative of involving patients and public in the MTEP programme through 
the Patient and  Public Involvement Programme PPIP [5], the guidelines do not explicitly detail the 
involvement of patients in the decision-making process. Through the process, people and organisations 
may register their interest in a technology, and they may be invited to attend  the committee meetings [5]. 
Also, they may participate and provide input in the consultation process of the draft recommendation. 
Nevertheless, the guidelines do not explicitly show the extent of patient contribution in the final MTG.  
Although technologies selected for MTG are the ones deemed to be cost-saving or cost-neutral, the 
Methods guide [10] does not clarify what would happen if they are found to be cost -incurring during the 
evaluation. Even if cost-incurring, they could still represent a beneficial and cost-effective use of NHS 
resources, and so rejecting them on that basis may not be appropriate. Also, by adopting a cost-
consequence approach, the committee is not in a position to evaluate value-for-money.  
1.5.6 Strengths and weaknesses of the review 
The review has several strengths. This is the first review to critically assess all the published MTGs 
stemming from the MTEP. Adopting a systematic approach, an overview of both the clinical and 
economic evidence underpinning the decision process in the MTGs was provided. It also incorporates a 
qualitative appraisal of the not-supported MTGs, identifying factors that could explain the key drivers of 
the committee decisions.  
There were a number of limitations to this review: the guidelines were reviewed by 1 investigator and 
then discussed with senior members of the team. Also, a small degree of inconsistency in the reporting of 
MTGs complicated the appraisal and comparison of the guidance documents. In the economic evaluation 
analyses, an average result of the economic evaluation was calculated by extracting minimum and 
maximum values from the MTGs, but this is likely to have limited comparability between the sponsors 
and EAC values. The qualitative assessment was limited to not-supported MTGs. Conducting a 
qualitative evaluation for identifying the key drivers of the positive decisions was beyond the scope of 
this review and should be investigated in future evaluations.  
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1.5.7 Unanswered questions and future research 
A number of MTGs stated that the evidence on the technology will be updated when it becomes 
available (e.g., MTG 22). NICE is currently updating 2 MTGs (20 and 21). Future investigations should 
monitor the evolution of the MTGs: as pointed out by Drummond and colleagues, medical technologies 
are routinely modified, with frequent changes in their clinical and economic implications [20]. Also, it 
would be interesting to evaluate further the supported and partially supported MTGs to look for other 
drivers in the decision making process that were not assessed in this review. Finally, future research 
should evaluate the extent to which medical technologies recommended by the MTEP are adopted in the 
NHS and their subsequent economic implications.  
1.5.8 Conclusions 
In conclusion, the MTEP programme has to date published 31 MTGs, supporting the adoption of 
most technologies, either fully or partially. Most of the MTGs did not have RCTs in the clinical evidence 
presented for the committees’ evaluation, regardless of the recommendation status, which may reflect the 
feasibility challenges of conducting RCTs for certain medical technologies. According to our review, the 
EAC played a significant role in the MTEP process. Overall, the EACs rejected 278 and added 59 studies 
to the sponsors’ submissions. Also, it suggested changes to the sponsors’ economic model, which had an 
impact on the final values in 84% of the cases (26/31). The main drivers of the decision in the not-
supported MTGs was the lack of quantity or quality of the evidence, as well as economic models with 
cost-incurring results in half of the cases (3/6).  
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are available.  
 
Author Contributions 
HN, EB, LO, and EM conceived the study. FC performed the document review, completed all data 
extraction, and developed the first full draft of the paper. All authors critically reviewed and contributed 
to subsequent drafts. All authors have read and approved the final version of the paper for submission.  
 
  
14 
 
1.6 TABLES (IN SEPARATE DOCUMENT) 
 
1. Table 1. Summary of the MTGs 
2. Table 2. Clinical Evidence Appraisal  
3. Table 3. Economic Evaluation Appraisal  
 
1.7 FIGURES (IN SEPARATE DOCUMENT) 
 
1. Figure 1. MTEP pathway  
2. Figure 2. Committee’s recommendation on Adoption  
3. Figure 3. RCTs evaluated by the committee according to Committee’s recommendation on 
adoption  
4. Figure 4. Clinical evidence evaluated by the committee according to Committee’s 
recommendation on adoption. 
5. Figure 5. Difference in the estimated cost savings by the sponsor and EAC (GBP).   
 
1.8 SUPPLEMENT (IN SEPARATE DOCUMENT) 
 
1. Supplement 1. Parameters description 
2. Supplement 2 Extended Economic Evaluation  
3. Supplement 3. Calculations 
4. Supplement 4. Qualitative evaluation: Clinical evidence EAC key criticisms from not supported 
MTGs 
5. Supplement 5. Qualitative evaluation: Economic evaluation EAC key criticisms from not 
supported MTGs  
 
 
 
 
 
  
15 
 
1.9 REFERENCES 
 
1. WHO: Health technology assessment of medical devices: WHO Medical device technical series. In: 
World Health Organization  (ed.). (2011) 
2. HTA Glossary: International Network of Agencies for Health Technology Assessment and Health 
Technology Assessment international. http://www.htaglossary.net.  
3. Raftery, J., Powell, J.: Health Technology Assessment in the UK. The Lancet 382(9900), 1278-1285 
(2013). doi:10.1016/S0140-6736(13)61724-9 
 
4. Chapman, A.M., Taylor, C.A., Girling, A.J.: Are the UK Systems of Innovation and Evaluation of 
Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation 
Programme (MTEP). Applied Health Economics and Health Policy 12(4), 347-357 (2014). 
doi:10.1007/s40258-014-0104-y 
 
5. NICE: Medical Technologies Evaluation Programme:  Process guide   In. London, (2011) 
 
6. NICE: Guide to the processes of technology  appraisal   In: National Institute for Health Care 
Excellence (ed.). (2014) 
 
7. NICE: Diagnostics Assessment Programme manual. In: National Institute for Health Care Excellence 
(ed.). (2011) 
8. NICE: Developing NICE guidelines: the manual. In: National Institute for Health Care Excellence 
(ed.). (2014) 
9. NICE: Interventional procedures programme manual. In: National Institute for Health Care Excellence 
(ed.). (2016) 
10. NICE: Medical Technologies Evaluation Programme:  Methods guide   In: National Institute for 
Health Care Excellence (ed.). London, (2011) 
 
11. Alshreef, A., Jenks, M., Green, W., Dixon, S.: Review of Economic Submissions to NICE Medical 
Technologies Evaluation Programme. Appl Health Econ Health Policy 14(6), 623-634 (2016). 
doi:10.1007/s40258-016-0262-1 
 
12. Ciani, O., Federici, C., Tarricone, R., Bezerianos, A.: Current and Future Trends in the HTA of 
Medical Devices. In book: XIV Mediterranean Conference on Medical and Biological Engineering and 
Computing (2016). doi:10.1007/978-3-319-32703-7_257 
 
13. Rothery, C., Claxton, K., Palmer, S., Epstein, D., Tarricone, R., Sculpher, M.: Characterising 
Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. 
Health Economics 26(S1), 109-123 (2017). doi:10.1002/hec.3467 
 
14. NICE: Research Recommendations  Process and methods guide In.National Institute for Health Care 
Excellence (ed.).United Kingdom, (2011) 
 
15. Pomfrett, C., Campbell, B., Pugh, P., Campbell, M., Marlow, M.: Medical technology evaluation II: 
catalysing  the development of primary clinical evidence for promising technologies. Paper 
presented at the 9th HTAi Annual Meeting, Bilbao (2012). 
 
16. Cowles, E., Marsden, G., Cole, A., Devlin, N.: A Review of NICE Methods and Processes Across 
Health Technology Assessment Programmes: Why the Differences and What is the Impact? 
Appl Health Econ Health Policy 15(4), 469-477 (2017). doi:10.1007/s40258-017-0309-y 
 
16 
 
17. Green, W., Hutton, J.: Health technology assessments in England: an analysis of the NICE Medical 
Technologies Evaluation Programme. Eur J Health Econ 15(5), 449-452 (2014). 
doi:10.1007/s10198-013-0539-3 
 
18. Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., 
Briggs, A.H., Mauskopf, J., Loder, E.: Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) statement. Bmj 346, f1049 (2013). doi:10.1136/bmj.f1049 
 
19. White, J., Ivins, N., Wilkes, A., Carolan-Rees, G., Harding, K.G.: Non-contact low-frequency 
ultrasound therapy compared with UK standard of care for venous leg ulcers: a single-centre, 
assessor-blinded, randomised controlled trial. Int Wound J 13(5), 833-842 (2016). 
doi:10.1111/iwj.12389 
 
20. Drummond, M., Griffin, A., Tarricone, R.: Economic evaluation for devices and drugs--same or 
different? Value Health 12(4), 402-404 (2009). doi:10.1111/j.1524-4733.2008.00476_1.x 
 
21. Schnell-Inderst, P., Hunger, T., Conrads-Frank, A., Arvandi, M., Siebert, U.: Recommendations for 
primary studies evaluating therapeutic medical devices were identified and systematically 
reported through reviewing existing guidance. J Clin Epidemiol 94, 46-58 (2018). 
doi:10.1016/j.jclinepi.2017.10.007 
 
22. Schnell-Inderst, P., Iglesias, C.P., Arvandi, M., Ciani, O., Matteucci Gothe, R., Peters, J., Blom, 
A.W., Taylor, R.S., Siebert, U.: A bias-adjusted evidence synthesis of RCT and observational 
data: the case of total hip replacement. Health Econ 26 Suppl 1, 46-69 (2017). 
doi:10.1002/hec.3474 
 
